Grabenbauer Gerhard G, Lahmer Godehard, Distel Luitpold, Niedobitek Gerald
Department of Radiation Oncology, Friedrich Alexander University, Erlangen, Germany.
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3355-60. doi: 10.1158/1078-0432.CCR-05-2434.
Tumor-infiltrating lymphocytes (TIL) are a possible prognostic factor in solid tumors. Cytotoxic TILs are generally considered as prognostically favorable, whereas regulatory T cells (Treg) may have adverse effects by virtue of their ability to inhibit effector cells. We have evaluated the effect of T-cell subsets on survival in patients with anal squamous cell carcinoma following radiochemotherapy.
Biopsy specimens from 38 patients with anal carcinomas were evaluated using tissue microarrays and immunohistochemistry for the presence of tumor-infiltrating immune cells using CD3, CD4, CD8, and CD68 antibodies. Treg were identified using an antibody directed against the transcription factor FoxP3, and granzyme B served as a marker for cytotoxic cells. Intratumoral immune cells were enumerated using a semiautomatic image analysis program. Prognostic effect of TIL subsets was evaluated by the log-rank test comparing no evidence of disease survival for groups with high and low numbers using median values as cutoff.
CD3+ and CD4+ TILs influenced no evidence of disease survival: 3-year rates for patients with low numbers were 89% and 95%, respectively, and 54% (P = 0.02) and 48%, (P = 0.01), respectively, in cases with high numbers. Large numbers of tumor-infiltrating granzyme B+ cytotoxic cells had a significant negative prognostic effect (P = 0.008), whereas no effect was observed for Treg.
TILs were identified as negative prognostic indicators in anal squamous cell carcinomas with granzyme B+ cytotoxic cells showing highest effect on outcome. This is possibly explained by the selection of therapy-resistant tumor cell clones. No prognostic influence of Treg was found. Knowledge of local immune responses is important for the development of immunotherapeutic strategies.
肿瘤浸润淋巴细胞(TIL)可能是实体瘤的一个预后因素。细胞毒性TIL通常被认为预后良好,而调节性T细胞(Treg)可能因其抑制效应细胞的能力而产生不利影响。我们评估了T细胞亚群对肛管鳞状细胞癌患者放化疗后生存的影响。
使用组织微阵列和免疫组织化学,用CD3、CD4、CD8和CD68抗体评估38例肛管癌患者活检标本中肿瘤浸润免疫细胞的存在情况。使用针对转录因子FoxP3的抗体鉴定Treg,颗粒酶B作为细胞毒性细胞的标志物。使用半自动图像分析程序对瘤内免疫细胞进行计数。通过对数秩检验评估TIL亚群的预后效应,以中位数为临界值比较高低数量组的无疾病生存证据。
CD3⁺和CD4⁺TIL对无疾病生存证据无影响:低数量患者的3年生存率分别为89%和95%,高数量患者分别为54%(P = 0.02)和48%(P = 0.01)。大量肿瘤浸润颗粒酶B⁺细胞毒性细胞具有显著的负面预后效应(P = 0.008),而未观察到Treg有此效应。
TIL被确定为肛管鳞状细胞癌的负面预后指标,其中颗粒酶B⁺细胞毒性细胞对预后影响最大。这可能是由于选择了对治疗耐药的肿瘤细胞克隆所致。未发现Treg有预后影响。了解局部免疫反应对免疫治疗策略的制定很重要。